CG Oncology
CGON
111 hedge funds and large institutions have $1.37B invested in CG Oncology in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 46 increasing their positions, 17 reducing their positions, and 17 closing their positions.
171% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 17
88% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 17
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
16% more funds holding
Funds holding: 96 → 111 (+15)
20% less capital invested
Capital invested by funds: $1.7B → $1.37B (-$336M)
23.91% less ownership
Funds ownership: 88.84% → 64.94% (-24%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $739K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$75.5M |
| 2 |
YF
Yu Fan
|
+$54.7M |
| 3 |
RI
RTW Investments
New York
|
+$32.2M |
| 4 |
State Street
Boston,
Massachusetts
|
+$21.9M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$18.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$33.7M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$22.3M |
| 3 |
PA
Perceptive Advisors
New York
|
-$19.8M |
| 4 |
Millennium Management
New York
|
-$18.9M |
| 5 |
BlackRock
New York
|
-$18.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
126
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$54.7K | -1,246 | Closed |
|
|
C
127
Covestor
London,
United Kingdom
| – | +$139 | +4 | New |
|
128
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$416 | +12 | New |
|
CGON Hedge Fund Activity: Q2 2024 in Review
111 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q2 2024, worth a combined $1.37B — down 20% from $1.7B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CGON positions and 17 closed out — a net gain of 15 holders — while 46 added to existing stakes and 17 trimmed.
The largest buyer was Braidwell, adding an estimated $75.5M. The largest seller was Holocene Advisors, exiting entirely with an estimated $33.7M sold.
- 111 institutional investors held CG Oncology (CGON) as of Q2 2024, up from 96 in Q1 2024.
- Funds reported $1.37B of CG Oncology stock for Q2 2024, down 20% quarter-over-quarter.
- 32 funds opened new CG Oncology positions in Q2 2024 and 17 closed out, a net change of +15 holders.
- The largest CG Oncology buyer in Q2 2024 was Braidwell, an estimated $75.5M added.
- The largest CG Oncology seller in Q2 2024 was Holocene Advisors, an estimated $33.7M sold.
Based on aggregated 13F filings for Q2 2024.